Navigation Links
Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
Date:11/1/2011

HONG KONG, Nov. 1, 2011 /PRNewswire/ -- OrbusNeich today announced that data from REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), a randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Dual Therapy Stent), will be presented in the Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 in San Francisco. The presentation entitled "REMEDEE: A Prospective, Randomized Trial of a Combination Bioabsorbalble Polymer-based Anti-CD34 Antibody Sirolimus-Eluting Stent vs. a Durable Polymer-based Paclitaxel-Eluting Stent" by Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will take place at 11:10 a.m. PST on Nov. 11 in the main arena.

The REMEDEE trial was designed to demonstrate the safety and effectiveness of the Combo Dual Therapy Stent compared to the TAXUS® Liberte® paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. This objective was measured in patients by a comparison of in-stent late lumen loss at nine months post-procedure. The trial included 183 patients at sites in Asia, Australia, Europe and South America.

On Thursday, Nov. 10, the Combo Dual Therapy Stent will be featured in a REMEDEE Breakfast Symposium titled "The New Combo Dual Therapy Stent." The symposium will be chaired by Martin B. Leon, M.D., and Alexandre Abizaid, M.D., and will take place at 7 a.m. PST in room 120. The symposium will provide an overview of the stent's underlying pro-healing technology, Genous, and the rationale of the REMEDEE study. Dr. Leon will introduce the new category of dual therapy stents, Roxana Mehran, M.D., will discuss the need for novel stents, Dr. Abizaid will describe the technology behind the Combo Dual Therapy Stent, and Michael Haude, M.D., will discuss the REMEDEE study design. Other presentations will include the OCT assessment of pro-healing stent coverage by Stephen W. L. Lee, M.D. Ulf Landmesser, M.D., and Mitchell W. Krucoff, M.D., will provide an overview about ongoing and relevant clinical investigations for the Combo Dual Therapy Stent.

Another presentation highlighting the Genous pro-healing stent technology is a talk entitled "A Prospective, Multicenter, Randomized Trial of the Early Healing of Four Types of Stents Assessed by Optical Coherence Tomography" by Ladislav Groch, M.D. This will take place at 7:45 p.m. PST on Tuesday, Nov. 8, in room 121.

About Combo Dual Therapy Stent

OrbusNeich's Combo Dual Therapy Stent is the only dual therapy stent that accelerates endothelial coverage and controls neointimal proliferation. The Combo Dual Therapy Stent combines the pro-healing technology used in the Genous™ Stent for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedical.

Editor's Notes: OrbusNeich will display the Combo Dual Therapy Stent, the Genous Stent and other products at booth No. 1429 at TCT 2011. Product images are available on request.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
2. CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India
3. Industrial Biotechnology China News 1109 - Annual Subscription
4. Cardiac Dimensions Announces First Patient Treated in TITAN II Clinical Trial
5. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
6. Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached
7. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
8. Circassias Hay Fever Treatment Improves Patients Allergy Symptoms in Phase II Clinical Trial
9. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
10. Roka Bioscience Initiates External Trial for AOAC Certification
11. Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology:
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
Breaking Biology News(10 mins):